Genmab | GEN - Current Liabilities


Genmab reported DKK1.14B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Almirall EUR 323.65M 26.99M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
Amgen USD 25.5B 547M Jun/2026
argenx SE USD 1.58B 254.81M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bayer EUR 32.27B 1.19B Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Demant DKK 12.42B 5B Jun/2026
Exelixis USD 361.93M 9.05M Jun/2026
Fresenius Medical Care EUR 7.18B 448.03M Jun/2026
Genmab DKK 1.14B 38M Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
GN Store Nord DKK 5.97B 1.15B Jun/2026
GRIFOLS EUR 2.24B 112M Jun/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Insmed USD 438.74M 77.74M Jun/2026
Lakefront Biotherapeutics EUR 70.32M 30.1M Jun/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 8.12B 1.22B Jun/2026
Novartis USD 31.75B 374M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
UCB EUR 4.4B 470M Dec/2025